Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04383223
Other study ID # IRB00114532
Secondary ID R34MH116805-01A1
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 28, 2020
Est. completion date June 30, 2024

Study information

Verified date October 2023
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Youth living with HIV are at high risk of falling out of care when they transition from pediatric to adult care. The investigators are proposing to develop a mobile app to help both clinical providers and patients navigate this process.


Description:

The transition from pediatric/adolescent to adult-oriented care settings can be disruptive to care engagement for youth living with HIV (YLH). The objective of this trial is to pilot and evaluate effectiveness of iTransition, an mHealth intervention to improve healthcare transition (HCT) at the patient, provider, and clinic levels.It is a prospective non-randomized intervention pilot trial of 128 subjects in Atlanta, GA and Philadelphia, PA: 100 YLH (50 intervention and 50 historical controls), 20 providers, and 8 Transition Champions. The study duration is 12 and 18 months for YLH and provider/champions, respectively. At baseline, YLH ≥18 years planning for care transition within 6 months, and reporting consistent internet access. Providers and Transition Champions must report working with transitioning YLH at pediatric/adolescent and/or adult HIV care centers. Data measures include iTransition usage, intervention satisfaction and health surveys, interviews (select participants), and medical chart review to measure clinical outcomes. The primary clinical outcome variable, measured at the patient-level, is linkage to adult care (defined dichotomously as having one completed adult clinic appointment or not). Secondary clinical outcomes are care retention (dichotomously defined as having or not having one visit in each 6-month period) and viral suppression (<200 copies/ml) at 1-year post-baseline visit.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 52
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: For YLH Historical Control Group - YLH (regardless of gender/assigned sex at birth) age = 18 years; - Has plan for HCT within next 6 months; - Enrolled in care at Grady IDP pediatric/adolescent clinic or CHOP AI/SI clinics. For YLH iTransition Intervention Group - YLH (regardless of gender/assigned sex at birth) age = 18 years; - Has plan for HCT within next 6 months; - Enrolled in care at Grady IDP pediatric/adolescent clinic or CHOP AI/SI clinics; - Owns a smartphone and/or tablet - Reports consistent internet access (defined as no lapse >24 hours in last 6 months) via their smartphone or tablet. For Provider Group - Staff member at Grady IDP (pediatric/adolescent clinic, adult women's clinic, and/or adult men's clinic), CHOP AI/SI clinics, UPHS: HUP or Presby infectious disease clinics; - Works with transitioning YLH; - Access to internet via any device (e.g., smartphone, tablet, computer); - Endorse participation in the HCT process. For Transition Champion Group - Staff member at Grady IDP (pediatric/adolescent clinic, adult women's clinic, and/or adult men's clinic), CHOP AI/SI clinics, UPHS: HUP or Presby infectious disease clinics; - Works with transitioning YLH; - Endorse participation in the HCT process; - Access to internet via any device (e.g., smartphone, tablet, computer); - Nominated by clinic staff where employed to be iTransition intervention point person (champion). Exclusion Criteria For YLH Historical Control Group - Youth who are <18 years old; - Youth who are not living with HIV; - Transition is not expected (from pediatric/adolescent to adult care) within the next 6 months; - Presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder) that would impair the individual's ability to provide true informed consent or participate in the study activities; - Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior) at the time of consent. For YLH iTransition Intervention Group - Youth who are <18 years old; - Youth who are not living with HIV; - Transition is not expected (from pediatric to adult care) within the next 6 months; - Does not own smartphone/tablet and has inconsistent internet access (i.e. has had one or more lapse >24 hrs in the last three months); - Presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder) that would impair the individual's ability to provide true informed consent or participate in the study activities; - Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior) at the time of consent. For Provider Group - Not a staff member at Grady IDP, CHOP SI/AI, UPHS: HUP or Presby infectious disease clinics; - Does not work with transitioning YLH; - Does not have access to internet via any device (e.g., smartphone, tablet, computer). For Transition Champion Group - Not a staff member at Grady IDP, CHOP SI/AI, UPHS: HUP or Presby infectious disease clinics; - Does not work with transitioning YLH; - Does not have access to internet via any device (e.g., smartphone, tablet, computer).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
iTransition
Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.

Locations

Country Name City State
United States Grady Hospital Atlanta Georgia
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States University of Pennsylvania Health System - HUP and Presby infectious disease clinics Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Emory University National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Linkage to adult care Defined dichotomously as having one completed adult clinic appointment or not. 18 month post-intervention
Secondary Change in Care retention Defined dichotomously as having one completed medical visit in each 6-month period. Baseline, 6 month post-intervention, 12 month post-intervention, 18-month post-intervention
Secondary Change in viral suppression Viral suppression is defined as <200 copies/ml blood at 1 year post-baseline. Baseline, 1-year post-intervention
See also
  Status Clinical Trial Phase
Terminated NCT03516318 - Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria N/A
Completed NCT04653194 - Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' Phase 3
Completed NCT01792570 - DRV/r + RPV QD: Efficacy and Toxicity Reduction Phase 3
Active, not recruiting NCT04826562 - Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Phase 4
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Completed NCT02919306 - Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Phase 1/Phase 2
Completed NCT02812329 - Intervention to Encourage HIV Testing and Counseling Among Adolescents Phase 1
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Completed NCT02516930 - A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China N/A
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT01944371 - Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study Phase 1/Phase 2
Recruiting NCT01778374 - Mater-Bronx Rapid HIV Testing Project. N/A
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT01076179 - Kaletra in Combination With Antiretroviral Agents N/A
Completed NCT01490346 - Tissue Drug Levels of HIV Medications N/A
Completed NCT01460433 - Problems With Immune Recovery in the Gut Tissue N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Terminated NCT04240210 - Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) Phase 4
Active, not recruiting NCT04704336 - Integration of Hypertension Management Into HIV Care in Nigeria N/A
Completed NCT03254277 - 3BNC117-LS First-in-Human Phase 1 Study Phase 1